Research programme: antibacterials - PALUMED

Drug Profile

Research programme: antibacterials - PALUMED

Alternative Names: Antibioquines; Hybrid antibacterials - PALUMED; PA 1046; PA 1409; Vancomyquine; Vancomyquine PA1409 (anti-MRSA drug)

Latest Information Update: 08 Jul 2016

Price : $50

At a glance

  • Originator PALUMED
  • Class Aminoquinolines; Cephalosporins; Glycopeptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bacterial infections; Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 15 Sep 2009 Antimicrobial, pharmacokinetic & pharmacodynamic data from preclinical trials of PA 1409 in Bacterial infections (including MRSA) presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009) ,,
  • 15 Sep 2009 Preclinical trials in Meticillin-resistant Staphylococcus aureus infections in France (unspecified route)
  • 21 Feb 2007 Preclinical trials in Bacterial infections in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top